Literature DB >> 28024733

Racial disparities in anaplastic oligodendroglioma: An analysis on 1643 patients.

Jacob Y Shin1, Ja Kyoung Yoon2, Aidnag Z Diaz2.   

Abstract

The objective of our study is to determine the influence of race on overall survival (OS) for anaplastic oligodendroglioma (AO). Data were extracted from the National Cancer Data Base (NCDB). Chi-square test, Kaplan-Meier method, and Cox regression models were employed in SPSS 22.0 (Armonk, NY: IBM Corp.) for data analyses. 1643 patients with AO were identified. 1386 (84.3%) were White, 83 (5.0%) Black, 133 (8.1%) Hispanic, and 41 (2.5%) were Asian. White and Black patients were significantly older than Hispanic and Asian patients (49.3% vs. 49.4% vs. 33.1% vs. 39.0%, p=0.003). Black patients were significantly less likely to be insured than White patients (12.8 vs. 7.2%, p<0.001) and significantly more likely to have lower income than other races (p<0.001). A trend towards higher comorbidity burden and lower rate of gross total resection was seen in Black patients. Black patients had significantly worse five-year OS compared to White, Hispanic, and Asian patients (40.3% vs. 52.3% vs. 67.8% vs. 67.7%, p=0.028). Of those who received adjuvant chemoRT, Black patients still had significantly worse OS compared to White patients (p=0.021). On multivariate analysis, Black race, older age at diagnosis, and not receiving adjuvant chemoradiotherapy were independent prognostic factors for worse OS in anaplastic oligodendroglioma. Future studies are warranted to help determine predictors for unfavorable molecular status, ways to optimize management of comorbidities, and interventions to help ensure adequate access to medical care for all patients to better care for those who may be at more risk for poorer outcome.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anaplastic oligodendroglioma; Disparities; Outcome; Race

Mesh:

Year:  2016        PMID: 28024733     DOI: 10.1016/j.jocn.2016.12.003

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  6 in total

Review 1.  Barriers to accrual and enrollment in brain tumor trials.

Authors:  Eudocia Q Lee; Ugonma N Chukwueke; Shawn L Hervey-Jumper; John F de Groot; Jose Pablo Leone; Terri S Armstrong; Susan M Chang; David Arons; Kathy Oliver; Kay Verble; Al Musella; Nicole Willmarth; Brian M Alexander; Amanda Bates; Lisa Doherty; Evanthia Galanis; Sarah Gaffey; Thomas Halkin; Bret E Friday; Maryam Fouladi; Nancy U Lin; David Macdonald; Minesh P Mehta; Marta Penas-Prado; Michael A Vogelbaum; Solmaz Sahebjam; David Sandak; Martin van den Bent; Michael Weller; David A Reardon; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2019-09-06       Impact factor: 12.300

2.  The Misclassification of Diffuse Gliomas: Rates and Outcomes.

Authors:  J Bryan Iorgulescu; Matthew Torre; Maya Harary; Timothy R Smith; Ayal A Aizer; David A Reardon; Jill S Barnholtz-Sloan; Arie Perry
Journal:  Clin Cancer Res       Date:  2019-01-11       Impact factor: 12.531

3.  Racial and ethnic differences in survival of pediatric patients with brain and central nervous system cancer in the United States.

Authors:  David A Siegel; Jun Li; Helen Ding; Simple D Singh; Jessica B King; Lori A Pollack
Journal:  Pediatr Blood Cancer       Date:  2018-10-23       Impact factor: 3.167

4.  Incidence trends, rates, and ethnic variations of primary CNS tumors in Texas from 1995 to 2013.

Authors:  Solomon N Ambe; Kristopher A Lyon; Damir Nizamutdinov; Ekokobe Fonkem
Journal:  Neurooncol Pract       Date:  2017-11-19

5.  Racial Differences in Hospital Stays among Patients Undergoing Craniotomy for Tumour Resection at a Single Academic Hospital.

Authors:  John P Sheppard; Carlito Lagman; Prasanth Romiyo; Thien Nguyen; Daniel Azzam; Yasmine Alkhalid; Courtney Duong; Isaac Yang
Journal:  Brain Tumor Res Treat       Date:  2019-10

6.  Disparities in Reported Testing for 1p/19q Codeletion in Oligodendroglioma and Oligoastrocytoma Patients: An Analysis of the National Cancer Database.

Authors:  Jad Zreik; Panagiotis Kerezoudis; Mohammed Ali Alvi; Yagiz U Yolcu; Sani H Kizilbash
Journal:  Front Oncol       Date:  2021-11-09       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.